BrainsWay Q4 Revenue $14.5M, Exceeds Consensus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 16 hours ago
0mins
Should l Buy BWAY?
Reports Q4 revenue $14.5M, consensus $14.02M. "We successfully closed out 2025 with strong momentum across our business, delivering 27% full-year revenue growth while significantly expanding profitability," said Hadar Levy, Chief Executive Officer of BrainsWay. "Demand for Deep TMS continues to accelerate, supported by expanding customer adoption, additional regulatory clearances, and growing reimbursement coverage. The FDA's recent clearance expanding Deep TMS MDD treatment to adolescents aged 15 to 21, and its clearance of our accelerated Deep TMS MDD protocol, represent meaningful growth catalysts for 2026 and beyond. In addition, our investment in Neurolief has the potential to significantly expand our addressable market and create new growth opportunities."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BWAY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BWAY
Wall Street analysts forecast BWAY stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 12.710
Low
19.00
Averages
26.33
High
30.00
Current: 12.710
Low
19.00
Averages
26.33
High
30.00
About BWAY
Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BrainsWay Shares Surge to All-Time High After Strong Q4 2025 Results
- Strong Financial Performance: BrainsWay reported Q4 revenue of $14.5 million, reflecting approximately 27% year-over-year growth and exceeding market expectations by $0.5 million, showcasing the company's robust growth potential in the MedTech sector.
- Significant Net Income Increase: The company's net income surged nearly 90% year-over-year to $2.9 million, surpassing estimates by $0.04 per share, indicating a substantial improvement in profitability.
- Optimistic Future Outlook: BrainsWay projects adjusted EBITDA for 2026 to be between $12 million and $14 million, representing an impressive 86% to 100% year-over-year growth, demonstrating confidence in future expansion.
- Substantial Increase in Performance Obligations: By year-end, the company's remaining performance obligations rose 43% year-over-year to approximately $70 million, highlighting strong future revenue potential and market demand.
See More
BrainsWay Ltd Reports Strong 2025 Earnings Growth
- Significant Revenue Growth: BrainsWay Ltd reported a 27% increase in revenue for both Q4 and full year 2025, reaching $14.5 million and $52.2 million respectively, demonstrating strong market performance and sustained profitability.
- Improved Gross Margin: The gross margin for Q4 2025 reached 76%, up from 75% in the previous year, indicating successful cost control and pricing strategies that enhance the company's competitive position in the market.
- Strong Cash Position: As of the end of 2025, BrainsWay Ltd held $68 million in cash and cash equivalents, providing robust financial support for future growth and strategic investments, ensuring continued expansion in the rapidly growing mental health market.
- Market Penetration Potential: Although approximately 1,700 Deep TMS systems have been installed, the company has captured less than 10% of the market, indicating significant future opportunities while facing challenges in expanding reimbursement coverage across the U.S.
See More
BrainsWay Q4 Earnings Beat Expectations, 2026 Outlook Positive
- Strong Earnings Report: BrainsWay reported a Q4 GAAP EPS of $0.07, beating expectations by $0.04, which indicates a sustained improvement in profitability and bolsters investor confidence.
- Significant Revenue Growth: The company achieved Q4 revenue of $14.55 million, reflecting a 27.5% year-over-year increase and surpassing market expectations by $0.53 million, highlighting strong demand and market share growth in the mental health sector.
- 2026 Financial Guidance: BrainsWay anticipates full-year 2026 revenue between $66 million and $68 million, representing a 27% to 30% growth compared to 2025, which exceeds the consensus estimate of $64.79 million, showcasing confidence in future growth.
- Profitability Outlook: The company expects to maintain profitability and positive cash flow, targeting an operating income of 13% to 14% and adjusted EBITDA of $12 million to $14 million, indicating a solid financial position that supports future expansion plans.
See More
BrainsWay to Announce Q4 Earnings on March 11
- Earnings Announcement: BrainsWay is set to release its Q4 earnings on March 11 before market open, with consensus EPS estimated at $0.03, reflecting a 25% year-over-year decline, while revenue is projected at $14.02 million, indicating a 22.9% year-over-year increase.
- Consistent Outperformance: Over the past year, BrainsWay has consistently beaten both EPS and revenue estimates, achieving a 100% success rate, which underscores its strong financial performance and market confidence.
- Investment Impact: Despite a recent decline in stock price following an investment in a Canadian mental care provider, BrainsWay remains a focal point in the industry, particularly given the ongoing demand for mental health services.
- Market Insights: According to Seeking Alpha's Quant Rating, BrainsWay's financial health is robust, and despite competitive pressures, its strategic positioning in the mental health market remains significant.
See More
GAD Therapies Market Expected to Reach $4.26B by 2033 Amid Rising Demand
- Market Growth Potential: The global market for Generalized Anxiety Disorder (GAD) treatments is projected to grow from $1.8 billion in 2023 to $4.26 billion by 2033, reflecting a robust annual growth rate of approximately 9%, driven by increasing awareness of mental health and demand for innovative solutions.
- Diverse Treatment Options: In addition to traditional anti-anxiety and antidepressant medications, the rise of cognitive-behavioral therapy and digital mental health tools has enhanced accessibility and effectiveness, allowing patients to manage symptoms in more flexible ways.
- Helus Pharma Drug Development: Helus Pharma announced positive topline results from its Phase 2 signal detection study for HLP004, indicating significant potential for this treatment to benefit adults with moderate-to-severe GAD who have not responded to existing therapies, thus offering new hope for underserved patients.
- Investment Outlook: As mental health care becomes increasingly integrated into mainstream healthcare systems, the broader anxiety treatment market is expected to exceed $12 billion in the next decade, with ongoing investments from companies and investors likely to drive long-term growth in this sector.
See More
GAD Therapies Market Expected to Reach $4.26B by 2033 Amid Rising Demand
- Market Growth Potential: The global market for generalized anxiety disorder (GAD) treatments is projected to grow from $1.8 billion in 2023 to $4.26 billion by 2033, reflecting a 9% annual growth rate driven by increasing awareness of mental health and demand for innovative solutions.
- Therapeutic Innovation: Helus Pharma's HLP004 demonstrated significant efficacy in a Phase 2 clinical trial for moderate-to-severe GAD patients, achieving an average reduction of 10.4 points in the Hamilton Anxiety Rating Scale (p<0.0001) within six weeks, offering new hope for patients who have not responded to existing treatments.
- Positive Patient Response: At six months, 67% of participants showed treatment response and 39% achieved remission, indicating that HLP004 provides durable effects and could potentially transform the treatment landscape for GAD.
- Optimistic Industry Outlook: The rise of digital mental health tools and telehealth has significantly improved treatment accessibility, and investments by Helus Pharma and other companies in mental health solutions are expected to drive continued market growth to meet the increasing patient demand.
See More
BrainsWay Shares Surge to All-Time High After Strong Q4 2025 Results
- Strong Financial Performance: BrainsWay reported Q4 revenue of $14.5 million, reflecting approximately 27% year-over-year growth and exceeding market expectations by $0.5 million, showcasing the company's robust growth potential in the MedTech sector.
- Significant Net Income Increase: The company's net income surged nearly 90% year-over-year to $2.9 million, surpassing estimates by $0.04 per share, indicating a substantial improvement in profitability.
- Optimistic Future Outlook: BrainsWay projects adjusted EBITDA for 2026 to be between $12 million and $14 million, representing an impressive 86% to 100% year-over-year growth, demonstrating confidence in future expansion.
- Substantial Increase in Performance Obligations: By year-end, the company's remaining performance obligations rose 43% year-over-year to approximately $70 million, highlighting strong future revenue potential and market demand.
See More
BrainsWay Ltd Reports Strong 2025 Earnings Growth
- Significant Revenue Growth: BrainsWay Ltd reported a 27% increase in revenue for both Q4 and full year 2025, reaching $14.5 million and $52.2 million respectively, demonstrating strong market performance and sustained profitability.
- Improved Gross Margin: The gross margin for Q4 2025 reached 76%, up from 75% in the previous year, indicating successful cost control and pricing strategies that enhance the company's competitive position in the market.
- Strong Cash Position: As of the end of 2025, BrainsWay Ltd held $68 million in cash and cash equivalents, providing robust financial support for future growth and strategic investments, ensuring continued expansion in the rapidly growing mental health market.
- Market Penetration Potential: Although approximately 1,700 Deep TMS systems have been installed, the company has captured less than 10% of the market, indicating significant future opportunities while facing challenges in expanding reimbursement coverage across the U.S.
See More
BrainsWay Q4 Earnings Beat Expectations, 2026 Outlook Positive
- Strong Earnings Report: BrainsWay reported a Q4 GAAP EPS of $0.07, beating expectations by $0.04, which indicates a sustained improvement in profitability and bolsters investor confidence.
- Significant Revenue Growth: The company achieved Q4 revenue of $14.55 million, reflecting a 27.5% year-over-year increase and surpassing market expectations by $0.53 million, highlighting strong demand and market share growth in the mental health sector.
- 2026 Financial Guidance: BrainsWay anticipates full-year 2026 revenue between $66 million and $68 million, representing a 27% to 30% growth compared to 2025, which exceeds the consensus estimate of $64.79 million, showcasing confidence in future growth.
- Profitability Outlook: The company expects to maintain profitability and positive cash flow, targeting an operating income of 13% to 14% and adjusted EBITDA of $12 million to $14 million, indicating a solid financial position that supports future expansion plans.
See More
BrainsWay to Announce Q4 Earnings on March 11
- Earnings Announcement: BrainsWay is set to release its Q4 earnings on March 11 before market open, with consensus EPS estimated at $0.03, reflecting a 25% year-over-year decline, while revenue is projected at $14.02 million, indicating a 22.9% year-over-year increase.
- Consistent Outperformance: Over the past year, BrainsWay has consistently beaten both EPS and revenue estimates, achieving a 100% success rate, which underscores its strong financial performance and market confidence.
- Investment Impact: Despite a recent decline in stock price following an investment in a Canadian mental care provider, BrainsWay remains a focal point in the industry, particularly given the ongoing demand for mental health services.
- Market Insights: According to Seeking Alpha's Quant Rating, BrainsWay's financial health is robust, and despite competitive pressures, its strategic positioning in the mental health market remains significant.
See More
GAD Therapies Market Expected to Reach $4.26B by 2033 Amid Rising Demand
- Market Growth Potential: The global market for Generalized Anxiety Disorder (GAD) treatments is projected to grow from $1.8 billion in 2023 to $4.26 billion by 2033, reflecting a robust annual growth rate of approximately 9%, driven by increasing awareness of mental health and demand for innovative solutions.
- Diverse Treatment Options: In addition to traditional anti-anxiety and antidepressant medications, the rise of cognitive-behavioral therapy and digital mental health tools has enhanced accessibility and effectiveness, allowing patients to manage symptoms in more flexible ways.
- Helus Pharma Drug Development: Helus Pharma announced positive topline results from its Phase 2 signal detection study for HLP004, indicating significant potential for this treatment to benefit adults with moderate-to-severe GAD who have not responded to existing therapies, thus offering new hope for underserved patients.
- Investment Outlook: As mental health care becomes increasingly integrated into mainstream healthcare systems, the broader anxiety treatment market is expected to exceed $12 billion in the next decade, with ongoing investments from companies and investors likely to drive long-term growth in this sector.
See More
GAD Therapies Market Expected to Reach $4.26B by 2033 Amid Rising Demand
- Market Growth Potential: The global market for generalized anxiety disorder (GAD) treatments is projected to grow from $1.8 billion in 2023 to $4.26 billion by 2033, reflecting a 9% annual growth rate driven by increasing awareness of mental health and demand for innovative solutions.
- Therapeutic Innovation: Helus Pharma's HLP004 demonstrated significant efficacy in a Phase 2 clinical trial for moderate-to-severe GAD patients, achieving an average reduction of 10.4 points in the Hamilton Anxiety Rating Scale (p<0.0001) within six weeks, offering new hope for patients who have not responded to existing treatments.
- Positive Patient Response: At six months, 67% of participants showed treatment response and 39% achieved remission, indicating that HLP004 provides durable effects and could potentially transform the treatment landscape for GAD.
- Optimistic Industry Outlook: The rise of digital mental health tools and telehealth has significantly improved treatment accessibility, and investments by Helus Pharma and other companies in mental health solutions are expected to drive continued market growth to meet the increasing patient demand.
See More
